Latest Chantix Stories
A medication commonly used to help people stop smoking may have an unanticipated positive side effect for an entirely different vice: drinking alcohol.
According to a new study, the smoking-cessation drug varenicline (Chantix) carries too many risks and should be a last-resort option for trying to quit the habit.
Smokers who take the anti-smoking drug Chantix are not at higher risk of being hospitalized for psychiatric events such as depression, compared with smokers who use nicotine patches.
Smoking cigarettes is a dangerous habit that many are struggling to break, but for the smokers who choose to use one of the most popular smoking cessation drugs on the market, new warnings about the risk of serious cardiovascular events are on their way.
Healthy, middle-aged smokers who take the most popular smoking cessation drug on the market have a 72 percent increased risk of being hospitalized with a heart attack or other serious heart problem.
The FDA said on Thursday that Pfizer's drug to help smokers quit can lead to a small increase in heart problems in those who have cardiovascular disease.
The FDA is tightening up on smoking cessation drugs, Chantix and Zyban, by requiring the drugs to be labeled with safety warnings over side effects including depression and suicidal thoughts.
The U.S. Food and Drug Administration announced Wednesday it will require a boxed warning for the smoking cessation drugs Chantix and Zyban. The FDA said the boxed warning -- the strongest warning the agency can require -- will appear on the package insert.
- A volcanic mudflow.